title: The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
abstract: Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal-related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.
authors: Amgen Inc., Thousand Oaks, California, USA. cgoessl@amgen.com
authors: Carsten
authors: C
authors: Goessl
authors: Leonid
authors: L
authors: Katz
authors: William C
authors: WC
authors: Dougall
authors: Paul J
authors: PJ
authors: Kostenuik
authors: Holly Brenza
authors: HB
authors: Zoog
authors: Ada
authors: A
authors: Braun
authors: Roger
authors: R
authors: Dansey
authors: Rachel B
authors: RB
authors: Wagman
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D001862:Bone Resorption / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D000069448:Denosumab; D055808:Drug Discovery; D006801:Humans; D010024:Osteoporosis / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D053245:RANK Ligand / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D053245:RANK Ligand; D000069448:Denosumab